Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

TSRI, Icahn School of Medicine and UPenn patent nAChR modulators

Dec. 15, 2016

Promising phase III topline results for CAM-2038 to treat moderate to severe opioid use disorder

Nov. 14, 2016

Omeros reports on phase II trial of PPARgamma agonist in heroin-dependent subjects

Nov. 3, 2016

Opiant Pharmaceuticals licenses heroin vaccine from WRAIR and NIDA

Nov. 3, 2016

Hawaii Biotech describes new Botulinum neurotoxin type A light chain inhibitors

Oct. 31, 2016

Omeros reports results from phase II study of PPARgamma agonist in cocaine use disorder

Oct. 20, 2016

U.K. Dstl gets funding to study inhaled ciprofloxacin in biodefense

Oct. 20, 2016

Addex initiates study of ADX-88178 in nonhuman primate model of cocaine addiction

Oct. 11, 2016

Phase II efficacy results for ABT-436 in alcohol-dependent subjects

Oct. 3, 2016

NIH dopamine D3 receptor antagonist VK-4-116 active in substance abuse models

Sep. 12, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...